Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects

• Published in: Antimicrobial agents and chemotherapy Vol. 62; no. 11
• Main Authors: Rodvold, Keith A., Gotfried, Mark H., Isaacs, Robin D., O'Donnell, John P., Stone, Emily
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.11.2018
• Subjects: Acinetobacter baumannii - drug effects; Acinetobacter Infections - blood; Acinetobacter Infections - drug therapy; Acinetobacter Infections - metabolism; Administration, Intravenous; Adult; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - blood; Anti-Bacterial Agents - metabolism; Azabicyclo Compounds; Azabicyclo Compounds - administration & dosage; Azabicyclo Compounds - blood; Azabicyclo Compounds - metabolism; Bronchoalveolar Lavage - methods; Bronchoalveolar Lavage Fluid - microbiology; Female; Healthy Volunteers; Humans; Macrophages, Alveolar - microbiology; Male; Middle Aged; Pharmacology; Pulmonary Alveoli - microbiology; Sulbactam; Sulbactam - administration & dosage; Sulbactam - blood; Sulbactam - metabolism; ETX2514SUL; pharmacokinetics; ETX2514; epithelial lining fluid; sulbactam; alveolar macrophages
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/AAC.01089-18

ETX2514 is a novel β-lactamase inhibitor that broadly inhibits Ambler class A, C, and D β-lactamases. ETX2514 combined with sulbactam (SUL) in vitro restores sulbactam activity against Acinetobacter baumannii . ETX2514 is a novel β-lactamase inhibitor that broadly inhibits Ambler class A, C, and D β-lactamases. ETX2514 combined with sulbactam (SUL) in vitro restores sulbactam activity against Acinetobacter baumannii . ETX2514-sulbactam (ETX2514SUL) is under development for the treatment of A. baumannii infections. The objective of this study was to determine and compare plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations following intravenous (i.v.) ETX2514 and sulbactam. Plasma, ELF, and AM concentrations of ETX2514 and sulbactam were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 30 healthy adult subjects following repeated dosing (ETX2514 [1 g] and sulbactam [1 g] every 6 h [q6h], as a 3-h i.v. infusion, for a total of 3 doses). A bronchoalveolar lavage (BAL) was performed once in each subject at either 1, 2.5, 3.25, 4, or 6 h after the start of the last infusion. Penetration ratios were calculated from area under the concentration-time curve from 0 to 6 h (AUC 0–6 ) values for total plasma and ELF using mean and median concentrations at the BAL fluid sampling times. Respective ELF AUC 0–6 values, based on mean and median concentrations, were 40.1 and 39.4 mg · h/liter for ETX2514 and 34.7 and 34.5 mg · h/liter for sulbactam. Respective penetration ratios of ELF to total/unbound plasma concentrations, based on mean and median AUC 0–6 values, of ETX2514 were 0.37/0.41 and 0.36/0.40, whereas these same ratio values were 0.50/0.81 and 0.50/0.80 for sulbactam. ETX2514 and sulbactam concentrations in AM were measurable and fairly constant throughout the dosing interval (median values of 1.31 and 1.01 mg/liter, respectively). These data support further study of ETX2514SUL for the treatment of pneumonia caused by multidrug-resistant A. baumannii . (This study has been registered at ClinicalTrials.gov under identifier NCT03303924.)